Spotlight on ixazomib: potential in the treatment of multiple myeloma

Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major ch...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drug Des Devel Ther
Asıl Yazarlar: Muz, Barbara, Ghazarian, Rachel Nicole, Ou, Monica, Luderer, Micah John, Kusdono, Hubert Daniel, Azab, Abdel Kareem
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2016
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4714737/
https://ncbi.nlm.nih.gov/pubmed/26811670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S93602
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller